242 related articles for article (PubMed ID: 22430336)
1. Otomycosis in immunocompetent and immunocompromised patients: comparative study and literature review.
Viswanatha B; Sumatha D; Vijayashree MS
Ear Nose Throat J; 2012 Mar; 91(3):114-21. PubMed ID: 22430336
[TBL] [Abstract][Full Text] [Related]
2. Povidone iodine soaked gelfoam for the treatment of recalcitrant otomycosis - Our experiences at a tertiary care teaching hospital of eastern India.
Swain SK; Behera IC; Sahu MC; Das A
J Mycol Med; 2018 Mar; 28(1):122-127. PubMed ID: 29223643
[TBL] [Abstract][Full Text] [Related]
3. Treatment of otomycosis with clotrimazole: results accordingly with the fungus isolated.
Antunes J; Mendes N; Adónis C; Freire F
Acta Otolaryngol; 2022; 142(9-12):664-667. PubMed ID: 36128634
[TBL] [Abstract][Full Text] [Related]
4. Various topical antifungal agents in otomycosis, which is the best?
Jwery AK
J Pak Med Assoc; 2021 Dec; 71(Suppl 8)(12):S32-S34. PubMed ID: 35130214
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the recovery rate of otomycosis using betadine and clotrimazole topical treatment.
Mofatteh MR; Naseripour Yazdi Z; Yousefi M; Namaei MH
Braz J Otorhinolaryngol; 2018; 84(4):404-409. PubMed ID: 28549873
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of topical clotrimazole in treatment of otomycosis.
Khan F; Muhammad R; Khan MR; Rehman F; Iqbal J; Khan M; Ullah G
J Ayub Med Coll Abbottabad; 2013; 25(1-2):78-80. PubMed ID: 25098061
[TBL] [Abstract][Full Text] [Related]
7. Aspergillus otomycosis in an immunocompromised patient.
Rutt AL; Sataloff RT
Ear Nose Throat J; 2008 Nov; 87(11):622-3. PubMed ID: 19006061
[TBL] [Abstract][Full Text] [Related]
8. Role of Clotrimazole in Prevention of Recurrent Otomycosis.
Kiakojuri K; Rajabnia R; Mahdavi Omran S; Pournajaf A; Karami M; Taghizadeh Armaki M
Biomed Res Int; 2019; 2019():5269535. PubMed ID: 31950041
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of topical clotrimazole vs. topical tolnaftate in the treatment of otomycosis. A randomized controlled clinical trial.
Jimenez-Garcia L; Celis-Aguilar E; Díaz-Pavón G; Muñoz Estrada V; Castro-Urquizo Á; Hernández-Castillo N; Amaro-Flores E
Braz J Otorhinolaryngol; 2020; 86(3):300-307. PubMed ID: 30826311
[TBL] [Abstract][Full Text] [Related]
10. Otomycosis in the north of Iran: common pathogens and resistance to antifungal agents.
Nemati S; Hassanzadeh R; Khajeh Jahromi S; Delkhosh Nasrollah Abadi A
Eur Arch Otorhinolaryngol; 2014 May; 271(5):953-7. PubMed ID: 23595615
[TBL] [Abstract][Full Text] [Related]
11. Administration of 1% topical voriconazole drops was effective and safe in the treatment of refractory otomycosis without tympanic membrane perforation.
Zhang S; Jin M; Hu S; Zhang Y; Zhou G
Ann Otol Rhinol Laryngol; 2021 Mar; 130(3):273-279. PubMed ID: 32772544
[TBL] [Abstract][Full Text] [Related]
12. Species distribution patterns and epidemiological characteristics of otomycosis in Southeastern Serbia.
Tasić-Otašević S; Golubović M; Đenić S; Ignjatović A; Stalević M; Momčilović S; Bojanović M; Arsić-Arsenijević V
J Mycol Med; 2020 Sep; 30(3):101011. PubMed ID: 32693980
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis.
de la Paz Cota BR; Cepero Vega PP; Matus Navarrete JJ; Aguado Mulgado GE; Narváez Huerta JJ; Lamadrid Bautista E; Fiscal Chauteco E
Am J Otolaryngol; 2018; 39(3):307-312. PubMed ID: 29551350
[TBL] [Abstract][Full Text] [Related]
14. Otomycosis in Shanghai: aetiology, clinical features and therapy.
Jia X; Liang Q; Chi F; Cao W
Mycoses; 2012 Sep; 55(5):404-9. PubMed ID: 21999222
[TBL] [Abstract][Full Text] [Related]
15. Clinical and microbial epidemiology of otomycosis in the city of Yasuj, southwest Iran, revealing Aspergillus tubingensis as the dominant causative agent.
Sabz G; Gharaghani M; Mirhendi H; Ahmadi B; Gatee MA; Sisakht MT; Hemati A; Mohammadi R; Taghavi J; Nouripour-Sisakht S
J Med Microbiol; 2019 Apr; 68(4):585-590. PubMed ID: 30801244
[TBL] [Abstract][Full Text] [Related]
16. Otomycosis in Africa: Epidemiology, diagnosis and treatment.
Sangaré I; Amona FM; Ouedraogo RW; Zida A; Ouedraogo MS
J Mycol Med; 2021 Jun; 31(2):101115. PubMed ID: 33516991
[TBL] [Abstract][Full Text] [Related]
17. Species identification and in vitro antifungal susceptibility testing of Aspergillus section Nigri strains isolated from otomycosis patients.
Kamali Sarwestani Z; Hashemi SJ; Rezaie S; Gerami Shoar M; Mahmoudi S; Elahi M; Bahardoost M; Tajdini A; Abutalebian S; Daie Ghazvini R
J Mycol Med; 2018 Jun; 28(2):279-284. PubMed ID: 29540288
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of otomycosis in Ibadan: a review of laboratory reports.
Fayemiwo SA; Ogunleye VO; Adeosun AA; Bakare RA
Afr J Med Med Sci; 2010 Dec; 39 Suppl():219-22. PubMed ID: 22420052
[TBL] [Abstract][Full Text] [Related]
19. Scedosporium apiospermum causing otomycosis in an immunocompetent child with tympanostomy tubes: Management of this rare entity.
Salamat AA; Archer C; Basarab A; Eren E; Batty V; Patel S; Salib RJ; Burgess A; Ismail-Koch H
Int J Pediatr Otorhinolaryngol; 2015 Oct; 79(10):1785-7. PubMed ID: 26298623
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Clotrimazole 1% Solution Compared to Econazole Nitrate 1% + Triamcinolone Acetonide 0.1% Cream in Patient with Otomycosis.
Mostafa MG; Ahmed S; Islam MR; Rahman MA; Khan L; Alam MM; Ahmed MB
Mymensingh Med J; 2021 Jul; 30(3):638-643. PubMed ID: 34226449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
